FR2308368A1 - Lysine salt of cephalexin - effect when administered parenterally as well as orally - Google Patents

Lysine salt of cephalexin - effect when administered parenterally as well as orally

Info

Publication number
FR2308368A1
FR2308368A1 FR7512916A FR7512916A FR2308368A1 FR 2308368 A1 FR2308368 A1 FR 2308368A1 FR 7512916 A FR7512916 A FR 7512916A FR 7512916 A FR7512916 A FR 7512916A FR 2308368 A1 FR2308368 A1 FR 2308368A1
Authority
FR
France
Prior art keywords
well
cephalexin
orally
infections
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7512916A
Other languages
French (fr)
Other versions
FR2308368B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antonio Gallardo SA
Original Assignee
Antonio Gallardo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antonio Gallardo SA filed Critical Antonio Gallardo SA
Priority to FR7512916A priority Critical patent/FR2308368A1/en
Publication of FR2308368A1 publication Critical patent/FR2308368A1/en
Application granted granted Critical
Publication of FR2308368B1 publication Critical patent/FR2308368B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antibiotic compsn. contains the lysine salt of cephalexin (7-(D-alpha-amino-alpha-phenylacetamido)-3-methyl-3-cephem-4-carb- oxylic acid) of formula (I) which is water soluble and may be administered by intramuscular or intravenous injection as well as orally. Cephalexin is insoluble in water and is well absorbed when administered orally. It is used to treat infections, especially those of the respiratory and urinary tracts, and is used prophylactically for post-operative infections. When the sodium or potassium salt is administered by injection it causes local pain and is poorly absorbed. This poor absorption has led to the use of other antibiotics, e.g cephaloridine for the initial parenteral treatment of acute infections followed later by the oral administration of cephalexin. This use of two different antibiotics, is inconvenient and antagonism occurs between them. The use of (I) which is well absorbed parenterally as well as orally overcomes these problems. The recommended intramuscular doses of (I) are 2-4g per day for adults, adn 30-50 mg/kg/day (rising to 100 mg/kg/day for serious infections) for children. (I) is a yellowish-white powder, m. pt 168-174 degrees C which dissolves in water to give a clear, yellow solution and is insoluble in ether and other non-polar solvents. (I) has LD50 in rats of 6g/kg s. c or i. p and in guinea pigs, 3-6g/kg s. c and 3g/kg i.p.
FR7512916A 1975-04-21 1975-04-21 Lysine salt of cephalexin - effect when administered parenterally as well as orally Granted FR2308368A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7512916A FR2308368A1 (en) 1975-04-21 1975-04-21 Lysine salt of cephalexin - effect when administered parenterally as well as orally

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7512916A FR2308368A1 (en) 1975-04-21 1975-04-21 Lysine salt of cephalexin - effect when administered parenterally as well as orally

Publications (2)

Publication Number Publication Date
FR2308368A1 true FR2308368A1 (en) 1976-11-19
FR2308368B1 FR2308368B1 (en) 1979-03-09

Family

ID=9154463

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7512916A Granted FR2308368A1 (en) 1975-04-21 1975-04-21 Lysine salt of cephalexin - effect when administered parenterally as well as orally

Country Status (1)

Country Link
FR (1) FR2308368A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225304B1 (en) 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190422A1 (en) * 1972-06-30 1974-02-01 Takeda Chemical Industries Ltd
FR2220533A1 (en) * 1973-03-08 1974-10-04 Gallardo Antonio Sa

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190422A1 (en) * 1972-06-30 1974-02-01 Takeda Chemical Industries Ltd
FR2220533A1 (en) * 1973-03-08 1974-10-04 Gallardo Antonio Sa

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225304B1 (en) 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals
US6492354B2 (en) 1999-02-17 2002-12-10 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
FR2308368B1 (en) 1979-03-09

Similar Documents

Publication Publication Date Title
MY108541A (en) Purine derivatives and use thereof in therapy.
IE41374L (en) Composition for treating schizophrenia
ATE27277T1 (en) THIENO(2,3-B)PYRROL DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
NO830686L (en) PROCEDURE FOR THE PREPARATION OF ERYTHROMYCIN DERIVATIVES
FR2363329A1 (en) 4-Carbamoyl-5-hydroxy-imidazole - used to treat cancer, nephritis and rheumatism
HUP9900438A2 (en) Use of pyrazolo[4,3-d]pyrimidin-7-one derivatives for the preparation of pharmaceutical compositions treaing impotence due to spinal cord injury
PT1102594E (en) USING SODIUM CHLORIDE TO REDUCE GASTROINTESTINAL TOXICITY OF CAMPTOTECIN DERIVATIVES
FR2308368A1 (en) Lysine salt of cephalexin - effect when administered parenterally as well as orally
NZ233704A (en) Dehydrocholecalciferol derivatives, pharmaceutical compositions thereof
FR2318649A1 (en) Treatment for rheumatism and cancer - contg. iodine, iodide, thiosulphate, polyvinyl pyrrolidone, an analgesic and an anaesthetic
GB1319868A (en) Antiviral medicines comprising rifamycin derivatives
IL66473A0 (en) Aminoglycoside derivatives,their production and pharmaceutical compositions containing them
FR2252103A1 (en) Hydroxamino-substd. oxazolobenzodiazepines - sedatives, muscle relaxants and anti-convulsants
JPS52128232A (en) Drugs for alleviating toxicity to kidneys
JPS54151134A (en) Antitumorigenic agent
JPS5527133A (en) Drug comprising organosilicon compound as main constituent
IE45096L (en) Thiadiazole derivatives
FR2320098A1 (en) Pyridylimino or quinolylimino-tetrahydro-thiazolo-isoquinoline cpds. - are analgesics and antipyretics with some antiinflammatory activity
JPS5610114A (en) Novel analgesic and anti-inflammatory agent
JPS5231051A (en) Preparation of amino sugar derivatives
GB1502727A (en) Bicyclic derivatives of 7-acylamido-3-cephem-4-carboxylic acid and process for their preparation
GB1279547A (en) N-arylidene derivatives of erythromycylamine
JPS5219647A (en) Preparation of 3-aminomethyl-4- homoisotwistane and its acid addition salt
FR2313923A1 (en) Compsn. contg. sodium noramidopyrin mesylate monohydrate - also contg. chlormezanone and meprobamate, having analgesic, antiinflammatory, muscle-relaxant and anxiolytic activity
FR2457869A1 (en) 6,9-di:oxo hexa:hydro thieno(2',3',4,5) pyrido (1,2-a) pyrazine - used as sedative and hypnotic having low toxicity prepd. from amine and 5-halo:acetyl 6-alkoxy-carbonyl tetra:hydro thieno (3,2-c) pyridine

Legal Events

Date Code Title Description
TP Transmission of property
CD Change of name or company name
ST Notification of lapse